arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

iSpecimen Inc.

ISPC
$2.23 ▲ +0.02 (+0.90%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
7
Health
Poor
Bearish
auto_awesome

Analytical Summary

iSpecimen Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -85.2%
Op. Margin None
ROIC -246.3%
FCF / Share $-9.85
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$156.01K
↓ -85.2%
Net Income Profit after all expenses
$-2.28M
↓ -37.2%
Operating Margin Operating profit as % of sales
-255.4%
↓ -64.9% 0th
FCF / Share Free cash flow per share
$-9.85
↓ -1987.7%
Long-Term Debt Long-term obligations
$3.43M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Financial Health
2
Cash Quality
36

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters